Financial Services

Anonymous, an international network of hackers, recently pledged to take on the financial services industry in a 30-day cyberattack campaign called “Operation Icarus,” more commonly referred to online as #OpIcarus. While the information about the group’s plan is somewhat spotty, various videos (purportedly, the group’s very own) and news articles indicate that the group is […]

Bank of America’s Q1 2016 earnings call had a bunch of fascinating information about where the company, and therefore financial services industry, is heading. Let’s start with the company’s financial investments in technology. Brian Moynihan, the CEO, said they continue to invest $3 billion annually on technology initiatives, with a deep focus in those that […]

IT system consolidations seems to be an ongoing trend in the financial services industry. In March, I shared J.P. Morgan’s plan to shrink the number of IT applications it uses by an overall 25%. Today, the story is about Deutsche Bank, Germany’s leading bank, who has a strong position in Europe and a significant presence […]

We frequently blog about FDA Warning Letters and other regulatory and compliance issues that revolve around traditional pharmaceuticals and medical devices. However, one product segment that we haven’t yet discussed is digital health. This is because digital health products are fairly new to the market and most are still trying to figure out how FDA […]

I don’t often see FDA Warning Letters issued to Institutional Review Boards (IRBs), so, when I came across this one, I thought it was worth sharing with you. This particular IRB was found to be in violation of 21 CFR Part 56.115(a)(2), related to meeting minutes, and 21 CFR Part 56.115(a)(5), related to a complete […]

My colleague, Mark Polly, wrote a post on Perficient’s digital transformation blog that highlighted the current state of digital marketing across various industries, including financial services. An infographic from CMO.com, an Adobe-operated website that offers digital marketing insight for chief marketing officers and senior marketing executives, indicates that digital channels are increasingly influencing product sales […]

I enjoy reading FDA Warning Letters. They’re insightful and often entertaining. Sometimes, though, they’re kind of unbelievable. And, sometimes, they’re downright nauseating. Take, for example, this letter issued on February 19, 2016 to a principal investigator (PI) based in New York. FDA inspectors found him to be in violation of 21 CFR Part 312.62(b), related […]

The next time you call Vanguard, your experience might be very different. One of the world’s largest investment management companies, with more than $3.2 trillion in global assets under management, has implemented voice verification technology. With voice verification, Vanguard can verify your identity simply by the sound of your voice. 

  In a recent post, I laid out three reasons why you should be a believer in Oracle. The article highlighted Oracle’s transition from focusing on solutions that were historically implemented on-premises to specializing in the development and sale of cloud solutions. 

  In a time when the turnover rate for clinical monitoring positions in the U.S. hovers around 25%, it’s more important than ever to do more with less. With risk-based monitoring (RBM), contract research organizations (CROs) and sponsors can leverage data in existing IT systems to spot, rectify, and prevent issues related to the execution […]

  Oracle Industry Connect, the conference designed for executives from a variety of industries, is right around the corner. Like, next week! To those of you planning to attend the event in Orlando from April 11-13, you’re in for a treat. There’s a powerful lineup of speakers who will be discussing the latest trends and […]

  Real-world data, the data generated about drugs and devices in real-world settings (e.g., routing doctor visits, hospital stays, etc.), can help develop more accurate product profiles. This is because the data comes from products that are no longer confined to the smaller, homogenous populations involved in clinical trials. More comprehensive profiles can help better […]